The 2026 GLP-1 landscape for Black women
Black women have the highest US obesity rate among women (about 57% per CDC 2024). GLP-1 medications represent the first treatment in decades to produce 15-20% sustained weight loss in clinical trials. Access is the issue: branded Wegovy and Zepbound run $1,000-$1,800/month at retail, most commercial insurance does not cover GLP-1 for weight loss, and Medicaid coverage is minimal in most states.
Compounded semaglutide from regulated compounding pharmacies (503A and 503B) became the access pathway for self-pay patients in 2022-2024. Hims Weight Loss is the largest single provider of compounded semaglutide in the US as of 2026.
The regulatory question
FDA declared the semaglutide shortage resolved in October 2024, which technically removed the legal basis for routine compounding. Enforcement has been gradual. As of 2026, compounded semaglutide is still available through services like Hims, but the regulatory ground is moving. If you start on compounded, plan for the possibility that you will need to transition to branded Wegovy or off the medication entirely in 2026-2027.
What the service includes
Standard intake covers BMI, comorbidities, contraindications (pancreatitis history, family history of medullary thyroid carcinoma, pregnancy planning). Dose titration is the standard 0.25 mg / 0.5 mg / 1 mg / 1.7 mg / 2.4 mg weekly schedule. Side-effect management is via async messaging with the clinical team. The higher-tier subscription adds behavior coaching, which Found bundles as standard.